NEW YORK (GenomeWeb News) – Oxford Gene Technology said today that it has acquired Cytocell for an undisclosed sum.

Cytocell, based in Cambridge, UK, offers a portfolio of fluorescence in situ hybridization probes that can be used to detect gene arrangements related to inherted diseases and cancer. Oxford, UK-based OGT said that Cytocell's products complement its CytoSure cytogenetics array and next-generation sequencing products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.